C$1.3 Million in Proceeds Received by The Precision Peptide Company from Warrant Exercises
Rhea-AI Summary
The Precision Peptide Company (OTCQB: PNGAF) received approximately C$1.3 million from the exercise of outstanding warrants on May 5, 2026.
Proceeds will strengthen the balance sheet and fund development and expansion of the Amino Innovations platform, including product rollout, delivery technology advancement, and North American distribution growth.
Positive
- C$1.3M cash received from warrant exercises
- Proceeds earmarked for Amino Innovations development and rollout
- Manufacturing in an approved U.S. facility supports supply chain
Negative
- Warrant exercises likely caused share dilution for existing holders
- No quantified runway impact or explicit allocation timeline provided
News Market Reaction – PNGAF
In the May 5 session, PNGAF gained 7.97%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") a publicly traded wellness company focused on advanced peptide formulations and delivery systems, announces the receipt of approximately C
The proceeds strengthen the Company's balance sheet and will be used to support the continued development and expansion of its Amino Innovations platform, including product rollout, delivery technology advancement, and distribution growth across North America.
BPC is focused on addressing a key limitation within the peptide category: delivery. While demand for peptide-based wellness solutions continues to grow, traditional formats have restricted broader adoption. The Company's approach centers on transdermal and oral delivery systems, including its developing peptide patch platform, designed to improve convenience and accessibility.
With products manufactured in an approved U.S. facility and a growing North American distribution footprint, BPC continues to position itself at the intersection of scientific formulation and scalable consumer wellness.
Pratap Sandhu, CEO of The Precision Peptide Company, commented:
"These proceeds are particularly well-timed. The regulatory landscape around peptides is evolving toward greater clarity and science-based standards. We believe this will favor credible operators with quality manufacturing and differentiated delivery technology, areas where BPC has invested deliberately. The capital received strengthens our ability to execute on that positioning and accelerate our pipeline and distribution buildout."
About The Precision Peptide Company
The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) is a publicly traded wellness company building a next-generation platform for high-quality peptide formulations. By combining scientific formulation and innovative delivery technologies, the Company creates products at the intersection of biotechnology and scalable consumer wellness. Products are manufactured in an approved U.S. facility and distributed across North America.
For more information, visit: www.precisionpeptidecompany.com
Company Contact
Pratap Sandhu
CEO, Corporate Secretary and Director
pratap@precisionpeptidecompany.com
+1 (604) 765-8069
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements in this news release, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the intended use of proceeds from the exercise of warrants; the development and expansion of the Company's Amino Innovations platform; including product rollout, delivery technology advancement, and distribution growth; the anticipated benefits of the Company's delivery systems; the evolving regulatory landscape; and the Company's business prospects, future plans and strategies.
In some cases, forward-looking statements can be identified by the use of words such as "may", "will", "would", "could", "should", "expects", "plans", "anticipates", "believes", "estimates", "projects", "potential", or the negative of these terms or other similar expressions intended to identify forward-looking statements.
Forward-looking statements in this news release are based on certain material assumptions and expectations of management, including, without limitation: that the proceeds from the exercise of warrants will be used as anticipated; that the Company will be able to advance its development and commercialization activities; and that general business and economic conditions will not change in a material adverse manner.
Although the Company believes that the assumptions and expectations reflected in the forward-looking statements are reasonable as at the date hereof, there can be no assurance that such assumptions and expectations will prove to be correct. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: the risk that the Company may not use the proceeds as currently contemplated; the risk that the Company may not be able to successfully develop or commercialize its products or delivery technology; and changes in general economic, market or business conditions.
Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295869